mRNA Coronavirus Disease 2019 Vaccine-Associated Myopericarditis in Adolescents: A Survey Study.
DOI: 10.1016/j.jpeds.2021.12.025; PMCID: PMC8691954
In this survey study of institutions across the US, marked variability in evaluation, treatment, and follow-up of adolescents 12 through 18 years of age with mRNA coronavirus disease 2019 (COVID-19) vaccine-associated myopericarditis was noted. Only one adolescent with life-threatening complications was reported, with no deaths at any of the participating institutions.
The Journal of pediatrics
Adolescent; COVID-19; COVID-19 Vaccines; Humans; Myocarditis; RNA, Messenger
mRNA COVID-19 vaccine-associated myopericarditis; outcomes; survey; variability
Kohli U, Desai L, Chowdhury D, et al. mRNA Coronavirus Disease 2019 Vaccine-Associated Myopericarditis in Adolescents: A Survey Study. J Pediatr. 2022;243:208-213.e3. doi:10.1016/j.jpeds.2021.12.025